What we do matters
The Institute is a powerhouse of scientific excellence, training, and innovation. This is achieved by the great position of the institute within the fantastic Strasbourg ecosystem. This competitiveness cluster includes leading institutions such as University of Strasbourg, University Hospitals and its close interaction with the IGBMC.
As we have a very strong culture of promoting cutting edge research, we are always seeking to collaborate with the very best and to promote programs of international importance. Our programs are funded by many prestigious awards including ERC Advanced grants, ARC TheraHCC, NIH, H2020.
RHU DELIVER
Laureate of the prestigious ANR call “Recherche Hospitalo-Universitaire en santé (RHU)”, DELIVER is a cutting-edge public-private R&D program that will combine patient-derived models, and integrate the latest imaging technologies with AI and large prospective cohorts of patients included in HCC surveillance programs, to deliver therapeutic innovation for advanced liver fibrosis and HCC.
To tackle this major challenge, world-class multidisciplinary teams from public and private sectors joined their forces: experts in translational liver disease research from Inserm, University of Strasbourg, IHU Strasbourg, Strasbourg University Hospitals, AP-HP Bobigny and University Sorbonne Paris Nord, will work together with the French-Swiss clinical stage rising star biotech Alentis, and the medical imaging leader Guerbet
ERC Advanced Grant HEPCIR
HEPCIR ERC program builds on the strengths of Prof. Baumert’s and his team’s track record in liver disease research to unravel the biological circuits underlying disease progression and liver cancer for the identification of novel targets and biomarkers. It has also been followed up by two ERC PoC grants highlighting the success of the program.
ERC Advanced Grant FIBCAN
FIBCAN ERC Advanced Grant 2020 program will focus on novel therapeutic approaches to treat and prevent advanced liver fibrosis and liver cancer, using innovative patient-derived models developed by Prof Baumert’s team.
ARC TheraHCC 2.0
Following the success of the TheraHCC program the institute is leading a follow-up program with the Strasbourg IHU and the University Hospitals of Strasbourg on the development of next generation precision medicine diagnostics and treatment for liver cancer with the continued support of the French National Cancer Foundation.
ARC TheraHCC 2.0
Following the success of the TheraHCC program the Inserm U1110 is leading a follow-up program with the Strasbourg IHU and the University Hospitals of Strasbourg on the development of next generation precision medicine diagnostics and treatment for liver cancer with the continued support of the French National Cancer Foundation.
The National Cancer Institute (NIH NCI US) funded study to systematically identify molecular liver cancer risk drivers based on decades of clinical follow-up, chemopreventive drugs, and less invasive cancer risk biomarker assays ready for subsequent clinical assessment. This program builds on the longstanding collaboration of Prof. Baumert’s team and Yujin Hoshida’s team at the UTSW.
In addition, we are part of the Scientific Excellence initiative ITI IMCBio. This cluster is built on the Graduate School IMCBio that was funded in 2017, and on four LabEx (INRT, NetRNA, Mitocross and our own HepSYS) federating five internationally recognized institutes associated with CNRS, Inserm and the University of Strasbourg.
This Biopole is based on:
- creating a continuum between advanced students training and research
- exploiting strong interdisciplinary expertise at the interface of biology
- using advanced infrastructures to decipher the complexity of living organisms and the mechanisms underlying human diseases
- promoting translation of fundamental knowledge to impactful discoveries
